GlassScriptPhysician profile
Aamir Adam Memon
NPI 1013074442
$5,862.90
in general payments reported to CMS, 2019-2025
33 companies · $1,948 in 2025
The $1,948 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $509 · 2020: $58.82 · 2021: $317 · 2022: $594 · 2023: $1,460 · 2024: $978 · 2025: $1,948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,177 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,177.08 |
| Education | $207.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,211.59 | 2019-2025 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $483.01 | 2019-2025 | Jynarque, Voyxact |
| Veloxis Pharmaceuticals, INC. | $441.57 | 2025 | Envarsus |
| Mallinckrodt Hospital Products INC. | $361.29 | 2023-2025 | Acthar, Terlivaz |
| Amgen INC. | $353.13 | 2023-2025 | Tavneos, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.21 | 2023-2024 | Jardiance |
| Ani Pharmaceuticals, INC. | $221.51 | 2023-2025 | Purified Cortrophin Gel |
| Opko Pharmaceuticals, LLC | $207.98 | 2023-2025 | Rayaldee |
| Vifor Pharma, INC. | $200.00 | 2021 | |
| Horizon Therapeutics Plc | $194.43 | 2022-2023 | Krystexxa |
| Akebia Therapeutics INC | $170.93 | 2020-2025 | Vafseo |
| Fresenius USA Marketing, INC. | $168.63 | 2023-2025 | Velphoro, Velphoro |
| Novartis Pharmaceuticals Corporation | $161.13 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $157.58 | 2024-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $133.67 | 2022-2025 | Arexvy, Shingrix |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $125.33 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $110.93 | 2025 | |
| Mallinckrodt Enterprises LLC | $99.91 | 2019 | |
| Ardelyx, INC. | $99.40 | 2024-2025 | Ibsrela |
| Biotronik INC. | $82.17 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $81.14 | 2025 | Voyxact |
| Aurinia Pharma U.S., INC. | $75.11 | 2022-2024 | Lupkynis |
| Alnylam Pharmaceuticals INC. | $73.35 | 2023-2024 | Oxlumo |
| Bard Peripheral Vascular, INC. | $68.50 | 2019 | |
| Novo Nordisk INC | $56.99 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.17 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.57 | 2023-2025 | Gattex, Livtencity |
| Shire North American Group INC | $37.62 | 2019 | |
| Apellis Pharmaceuticals, INC. | $24.24 | 2025 | |
| Daiichi Sankyo INC. | $22.98 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.31 | 2025 | Keveyis |
| Cycle Pharmaceuticals INC | $18.14 | 2025 | Venxxiva |
| Strongbridge US INC. | $15.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aamir Memon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.